A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose

Vaccine

Volumn 33, Issue 19, 2015, Pages 2261-2266

  Tsuda, Yoshimi ^a,f   Parkins, Christopher J ^b   Caposio, Patrizia ^b   Feldmann, Friederike ^a   Botto, Sara ^b   Ball, Susan ^c   Messaoudi, Ilhem ^d   Cicin Sain, Luka ^e   Feldmann, Heinz ^a   Jarvis, Michael A ^c  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF PLYMOUTH   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^f HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytomegalovirus; Disseminating; Durable; Ebola; Ebolavirus; Great apes; Mouse; Protection; Vaccine

Indexed keywords

CYTOMEGALOVIRUS VACCINE; VIRUS VACCINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; FEMALE; IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; VACCINATION; ZAIRE EBOLAVIRUS; ANIMAL; BODY WEIGHT; C57BL MOUSE; CYTOMEGALOVIRUS; DISEASE MODEL; EBOLAVIRUS; GENE VECTOR; GENETICS; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; PROCEDURES; SURVIVAL ANALYSIS;

ANIMALS; BODY WEIGHT; CYTOMEGALOVIRUS; DISEASE MODELS, ANIMAL; EBOLAVIRUS; FEMALE; GENETIC VECTORS; HEMORRHAGIC FEVER, EBOLA; MICE, INBRED C57BL; SURVIVAL ANALYSIS; VACCINATION; VIRAL VACCINES;

EID: 84929574655     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.03.029     Document Type: Article

References (37)

1. Gatherer D. The 2014 Ebola virus disease outbreak in west Africa. J Gen Virol 2014, 95:1619-1624.
2. Mari Saez A., Weiss S., Nowak K., Lapeyre V., Zimmermann F., Dux A., et al. Investigating the zoonotic origin of the west African Ebola epidemic. EMBO Mol Med 2014, 7:17-23.
3. Rizkalla C., Blanco-Silva F., Gruver S. Modeling the impact of Ebola and bushmeat hunting on western lowland gorillas. EcoHealth 2007, 4:151-155.
4. Groseth A., Feldmann H., Strong J.E. The ecology of Ebola virus. Trends Microbiol 2007, 15:408-416.
5. Leroy E.M., Rouquet P., Formenty P., Souquiere S., Kilbourne A., Froment J.M., et al. Multiple Ebola virus transmission events and rapid decline of central African wildlife. Science 2004, 303:387-390.
6. Rouquet P., Froment J.M., Bermejo M., Kilbourn A., Karesh W., Reed P., et al. Wild animal mortality monitoring and human Ebola outbreaks, Gabon and Republic of Congo, 2001-2003. Emerg Infect Dis 2005, 11:283-290.
7. Leroy E.M., Kumulungui B., Pourrut X., Rouquet P., Hassanin A., Yaba P., et al. Fruit bats as reservoirs of Ebola virus. Nature 2005, 438:575-576.
8. Prevention CfDCa. Ebola in Democratic Republic of the Congo. Alert-level 2, Practice enhanced precautions. 2014. (Online).
9. Walsh P.D., Abernethy K.A., Bermejo M., Beyers R., De Wachter P., Akou M.E., et al. Catastrophic ape decline in western equatorial Africa. Nature 2003, 422:611-614.
10. Bermejo M., Rodriguez-Teijeiro J.D., Illera G., Barroso A., Vila C., Walsh P.D. Ebola outbreak killed 5000 gorillas. Science 2006, 314:1564.
11. Formenty P., Boesch C., Wyers M., Steiner C., Donati F., Dind F., et al. Ebola virus outbreak among wild chimpanzees living in a rain forest of Cote d'Ivoire. J Infect Dis 1999, 179(Suppl 1):S120-S126.
12. Ryan S.J., Walsh P.D. Consequences of non-intervention for infectious disease in African great apes. PLoS One 2011, 6:e29030.
13. Warfield K.L., Goetzmann J.E., Biggins J.E., Kasda M.B., Unfer R.C., Vu H., et al. Vaccinating captive chimpanzees to save wild chimpanzees. Proc Natl Acad Sci USA 2014, 111:8873-8876.
14. Tsuda Y., Caposio P., Parkins C.J., Botto S., Messaoudi I., Cicin-Sain L., et al. A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus. PLoS Negl Trop Dis 2011, 5:e1275.
15. Mocarski E.S.J., Shenk T., Pass R.F. Cytomegalovirus. Fields Virology 2007, 2:2701-2772. Lippincott-Raven Publishers, Philadelphia. 5th ed.
16. Hansen S.G., Ford J.C., Lewis M.S., Ventura A.B., Hughes C.M., Coyne-Johnson L., et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011, 473:523-527.
17. Jarvis M.A., Hansen S.G., Nelson J.A., Picker L.J., Frueh K. Vaccine vectors using the unique biology and immunology of cytomegalovirus. Cytomegaloviruses: From Molecular Pathogenesis to Intervention 2012, II. Caister Academic Press, Poole, UK.
18. Redwood A.J., Messerle M., Harvey N.L., Hardy C.M., Koszinowski U.H., Lawson M.A., et al. Use of a murine cytomegalovirus K181-derived bacterial artificial chromosome as a vaccine vector for immunocontraception. J Virol 2005, 79:2998-3008.
19. Tierney R., Nakai T., Parkins C.J., Caposio P., Fairweather N.F., Sesardic D., et al. A single-dose cytomegalovirus-based vaccine encoding tetanus toxin fragment C induces sustained levels of protective tetanus toxin antibodies in mice. Vaccine 2012, 30:3047-3052.
20. Klyushnenkova E.N., Kouiavskaia D.V., Parkins C.J., Caposio P., Botto S., Alexander R.B., et al. A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer. J Immunother 2012, 35:390-399.
21. Ross S.A., Arora N., Novak Z., Fowler K.B., Britt W.J., Boppana S.B. Cytomegalovirus reinfections in healthy seroimmune women. J Infect Dis 2010, 201:386-389.
22. Farroway L.N., Gorman S., Lawson M.A., Harvey N.L., Jones D.A., Shellam G.R., et al. Transmission of two Australian strains of murine cytomegalovirus (MCMV) in enclosure populations of house mice (Mus domesticus). Epidemiol Infect 2005, 133:701-710.
23. Boppana S.B., Rivera L.B., Fowler K.B., Mach M., Britt W.J. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med 2001, 344:1366-1371.
24. Hansen S.G., Powers C.J., Richards R., Ventura A.B., Ford J.C., Siess D., et al. Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science 2010, 328:102-106.
25. Murthy S., Couacy-Hymann E., Metzger S., Nowak K., De Nys H., Boesch C., et al. Absence of frequent herpesvirus transmission in a nonhuman primate predator-prey system in the wild. J Virol 2013, 87:10651-10659.
26. Kern E.R. Pivotal role of animal models in the development of new therapies for cytomegalovirus infections. Antiviral Res 2006, 71:164-171.
27. Karrer U., Wagner M., Sierro S., Oxenius A., Hengel H., Dumrese T., et al. Expansion of protective CD8+ T-cell responses driven by recombinant cytomegaloviruses. J Virol 2004, 78:2255-2264.
28. Wong G., Richardson J.S., Pillet S., Patel A., Qiu X., Alimonti J., et al. Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci Transl Med 2012, 4:158ra146.
29. Bukreyev A., Marzi A., Feldmann F., Zhang L., Yang L., Ward J.M., et al. Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge. Virol 2009, 383:348-361.
30. Wang D., Raja N.U., Trubey C.M., Juompan L.Y., Luo M., Woraratanadharm J., et al. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus. J Virol 2006, 80:2738-2746.
31. Jones S.M., Feldmann H., Stroher U., Geisbert J.B., Fernando L., Grolla A., et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005, 11:786-790.
32. Kaech S.M., Wherry E.J. Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection. Immunity 2007, 27:393-405.
33. Munks M.W., Cho K.S., Pinto A.K., Sierro S., Klenerman P., Hill A.B. Four distinct patterns of memory CD8 T cell responses to chronic murine cytomegalovirus infection. J Immunol 2006, 177:450-458.
34. Hansen S.G., Vieville C., Whizin N., Coyne-Johnson L., Siess D.C., Drummond D.D., et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009, 15:293-299.
35. Baaten B.J., Tinoco R., Chen A.T., Bradley L.M. Regulation of antigen-experienced T cells: lessons from the quintessential memory marker CD44. Front Immunol 2012, 3:23.
36. Snyder C.M., Cho K.S., Bonnett E.L., van Dommelen S., Shellam G.R., Hill A.B. Memory inflation during chronic viral infection is maintained by continuous production of short-lived, functional T cells. Immunity 2008, 29:650-659.
37. Cush S.S., Flano E. KLRG1+NKG2A+CD8 T cells mediate protection and participate in memory responses during gamma-herpesvirus infection. J Immunol 2011, 186:4051-4058.